UTHR Q3 2018 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$413M-7.4% YoY

Gross Profit

$361M87.4% margin

Operating Income

$150M36.2% margin

Net Income

$107M25.8% margin

EPS (Diluted)

$2.42

QoQ Revenue Growth

-7.2%

Cash Flow

Operating Cash Flow

$238M

Free Cash Flow

$196M

Stock-Based Comp.

$51M

Balance Sheet

Total Assets

$3.4B

Total Liabilities

$700M

Stockholders' Equity

$2.7B

Cash & Equivalents

$656M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$413M	$446M	-7.4%
Gross Profit	$361M	$426M	-15.3%
Operating Income	$150M	$324M	-53.8%
Net Income	$107M	$276M	-61.5%

Revenue Segments

Remodulin

$154M37%

Tyvaso

$108M26%

Adcirca

$75M18%

Orenitram

$54M13%

Unituxin

$23M6%

Geographic Segments

U

$389M94%

European Union And Others

$24M6%